Patent application number | Description | Published |
20120220547 | FOOD FORMULATION COMPRISING GLYCOGEN - The present invention relates to a food formulation for the controlled release of glucose comprising glycogen and at least one other edible component, as well the use of glycogen for its preparation. | 08-30-2012 |
20120220636 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF MCP-1 MEDIATED INFLAMMATORY DISEASES - The present invention relates to a pharmaceutical composition comprising a combination of 1-benzyl-3-hydroxymethyl-indazole derivative, a pressure lowering agent selected from ACE-inhibitors, renin inhibitors, ARBs and CCBs, and/or a cholesterol lowering agent selected from statin derivatives. The combination showed an additive and synergistic activity in reducing MCP-1 levels, thus significantly improving inflammatory response inhibition and consequently reducing complications occurring in patients suffering from inflammatory diseases. | 08-30-2012 |
20120302618 | USE OF BENZYDAMINE IN THE TREATMENT OF P40-DEPENDENT DISEASES - Use of benzydamine in the treatment of inflammatory diseases, in particular Crohn's disease, rheumatoid arthritis, psoriatic arthritis, and psoriasis, caused by an expression or overexpression of the cytokine subunit p40. | 11-29-2012 |
Patent application number | Description | Published |
20100056539 | TRAZODONE AND TRAZODONE HYDROCHLORIDE IN PURIFIED FORM - A process of production of trazodone or trazodone hydrochloride that comprises the steps of: (a) preparing an organic phase comprising trazodone in at least one organic solvent; (b) preparing an aqueous phase comprising at least one basic compound; (c) mixing said aqueous phase with said organic phase; (d) heating at a temperature of at least 40° C. for at least 30 minutes; (e) recovering said trazodone; and, optionally, (f) treating said trazodone with hydrochloric acid to obtain trazodone hydrochloride. Trazodone or trazodone hydrochloride comprising less than 15 ppm of alkylating substances, and a pharmaceutical composition comprising said trazodone hydrochloride. | 03-04-2010 |
20120142699 | TRAZODONE AND TRAZODONE HYDROCHLORIDE IN PURIFIED FORM - A process of production of trazodone or trazodone hydrochloride that comprises: (a) preparing an organic phase comprising trazodone in at least one organic solvent; (b) preparing an aqueous phase comprising at least one basic compound; (c) mixing said aqueous phase with said organic phase; (d) heating at a temperature of at least 40° C. for at least 30 minutes; (e) recovering said trazodone; and, optionally, (f) treating said trazodone with hydrochloric acid to obtain trazodone hydrochloride. Trazodone or trazodone hydrochloride comprising less than 15 ppm of alkylating substances, and a pharmaceutical composition comprising said trazodone hydrochloride. | 06-07-2012 |
20130012520 | TRAZODONE AND TRAZODONE HYDROCHLORIDE IN PURIFIED FORM - A process of production of trazodone or trazodone hydrochloride that comprises: (a) preparing an organic phase comprising trazodone in at least one organic solvent; (b) preparing an aqueous phase comprising at least one basic compound; (c) mixing said aqueous phase with said organic phase; (d) heating at a temperature of at least 40° C. for at least 30 minutes; (e) recovering said trazodone; and, optionally, (f) treating said trazodone with hydrochloric acid to obtain trazodone hydrochloride. Trazodone or trazodone hydrochloride comprising less than 15 ppm of alkylating substances, and a pharmaceutical composition comprising said trazodone hydrochloride. | 01-10-2013 |
20140057922 | TRAZODONE AND TRAZODONE HYDROCHLORIDE IN PURIFIED FORM - A process of production of trazodone or trazodone hydrochloride that comprises: (a) preparing an organic phase comprising trazodone in at least one organic solvent; (b) preparing an aqueous phase comprising at least one basic compound; (c) mixing said aqueous phase with said organic phase; (d) heating at a temperature of at least 40° C. for at least 30 minutes; (e) recovering said trazodone; and, optionally, (f) treating said trazodone with hydrochloric acid to obtain trazodone hydrochloride. Trazodone or trazodone hydrochloride comprising less than 15 ppm of allylating substances, and a pharmaceutical composition comprising said trazodone hydrochloride. | 02-27-2014 |
20140296250 | TRAZODONE AND TRAZODONE HYDROCHLORIDE IN PURIFIED FORM - A process of production of trazodone or trazodone hydrochloride that comprises: (a) preparing an organic phase comprising trazodone in at least one organic solvent; (b) preparing an aqueous phase comprising at least one basic compound; (c) mixing said aqueous phase with said organic phase; (d) heating at a temperature of at least 40° C. for at least 30 minutes; (e) recovering said trazodone; and, optionally, (f) treating said trazodone with hydrochloric acid to obtain trazodone hydrochloride. Trazodone or trazodone hydrochloride comprising less than 15 ppm of alkylating substances, and a pharmaceutical composition comprising said trazodone hydrochloride. | 10-02-2014 |
20150105402 | TRAZODONE AND TRAZODONE HYDROCHLORIDE IN PURIFIED FORM - A process of production of trazodone or trazodone hydrochloride that comprises: (a) preparing an organic phase comprising trazodone in at least one organic solvent; (b) preparing an aqueous phase comprising at least one basic compound; (c) mixing said aqueous phase with said organic phase; (d) heating at a temperature of at least 40° C. for at least 30 minutes; (e) recovering said trazodone; and, optionally, (f) treating said trazodone with hydrochloric acid to obtain trazodone hydrochloride. Trazodone or trazodone hydrochloride comprising less than 15 ppm of allylating substances, and a pharmaceutical composition comprising said trazodone hydrochloride. | 04-16-2015 |
20150297589 | TRAZODONE AND TRAZODONE HYDROCHLORIDE IN PURIFIED FORM - A process of production of trazodone or trazodone hydrochloride that comprises: (a) preparing an organic phase comprising trazodone in at least one organic solvent; (b) preparing an aqueous phase comprising at least one basic compound; (c) mixing said aqueous phase with said organic phase; (d) heating at a temperature of at least 40° C. for at least 30 minutes; (e) recovering said trazodone; and, optionally, (f) treating said trazodone with hydrochloric acid to obtain trazodone hydrochloride. Trazodone or trazodone hydrochloride comprising less than 15 ppm of alkylating substances, and a pharmaceutical composition comprising said trazodone hydrochloride. | 10-22-2015 |
20160113926 | TRAZODONE AND TRAZODONE HYDROCHLORIDE IN PURIFIED FORM - A process of production of trazodone or trazodone hydrochloride that comprises: (a) preparing an organic phase comprising trazodone in at least one organic solvent; (b) preparing an aqueous phase comprising at least one basic compound; (c) mixing said aqueous phase with said organic phase; (d) heating at a temperature of at least 40° C. for at least 30 minutes; (e) recovering said trazodone; and, optionally, (f) treating said trazodone with hydrochloric acid to obtain trazodone hydrochloride. Trazodone or trazodone hydrochloride comprising less than 15 ppm of alkylating substances, and a pharmaceutical composition comprising said trazodone hydrochloride. | 04-28-2016 |
Patent application number | Description | Published |
20120220547 | FOOD FORMULATION COMPRISING GLYCOGEN - The present invention relates to a food formulation for the controlled release of glucose comprising glycogen and at least one other edible component, as well the use of glycogen for its preparation. | 08-30-2012 |
20120220636 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF MCP-1 MEDIATED INFLAMMATORY DISEASES - The present invention relates to a pharmaceutical composition comprising a combination of 1-benzyl-3-hydroxymethyl-indazole derivative, a pressure lowering agent selected from ACE-inhibitors, renin inhibitors, ARBs and CCBs, and/or a cholesterol lowering agent selected from statin derivatives. The combination showed an additive and synergistic activity in reducing MCP-1 levels, thus significantly improving inflammatory response inhibition and consequently reducing complications occurring in patients suffering from inflammatory diseases. | 08-30-2012 |
20120302618 | USE OF BENZYDAMINE IN THE TREATMENT OF P40-DEPENDENT DISEASES - Use of benzydamine in the treatment of inflammatory diseases, in particular Crohn's disease, rheumatoid arthritis, psoriatic arthritis, and psoriasis, caused by an expression or overexpression of the cytokine subunit p40. | 11-29-2012 |
Patent application number | Description | Published |
20120220547 | FOOD FORMULATION COMPRISING GLYCOGEN - The present invention relates to a food formulation for the controlled release of glucose comprising glycogen and at least one other edible component, as well the use of glycogen for its preparation. | 08-30-2012 |
20120220636 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF MCP-1 MEDIATED INFLAMMATORY DISEASES - The present invention relates to a pharmaceutical composition comprising a combination of 1-benzyl-3-hydroxymethyl-indazole derivative, a pressure lowering agent selected from ACE-inhibitors, renin inhibitors, ARBs and CCBs, and/or a cholesterol lowering agent selected from statin derivatives. The combination showed an additive and synergistic activity in reducing MCP-1 levels, thus significantly improving inflammatory response inhibition and consequently reducing complications occurring in patients suffering from inflammatory diseases. | 08-30-2012 |
20120302618 | USE OF BENZYDAMINE IN THE TREATMENT OF P40-DEPENDENT DISEASES - Use of benzydamine in the treatment of inflammatory diseases, in particular Crohn's disease, rheumatoid arthritis, psoriatic arthritis, and psoriasis, caused by an expression or overexpression of the cytokine subunit p40. | 11-29-2012 |
Patent application number | Description | Published |
20100217803 | INTERFACE DEVICE FOR COMMUNICATION BETWEEN A MEDICAL DEVICE AND A COMPUTER - The present invention relates to an interface device and a method for communication between a medical device and a computer system. In some embodiments, the interface device comprises a conversion device and/or a processor-transceiver and a memory in electrical communication with the conversion device, wherein the memory contains data to instruct the conversion device and/or the processor transceiver how to communicate with the medical device. | 08-26-2010 |
20110087756 | Method and Apparatus for Displaying Data from Medical Devices - The invention, in one aspect, relates to a system for providing for the display of data from a plurality of non-homogeneous medical devices. In one embodiment the system includes a local authority to receive data using a first protocol from the medical devices and convert the data to a second protocol, a central authority in communication with the local authority, and a user interface, in communication with the central authority. The central authority routes data that has been converted to a second protocol for display by the user interface. | 04-14-2011 |
20120095304 | System and Method for Determining a Patient Clinical Status - A system and method for displaying a patient clinical status. In one embodiment, the system includes a plurality of sensors, each sensor measuring a respective patient parameter; a processor in communication with each of the plurality of sensors, and a display in communication with the processor. The processor receives the patient parameters and generates a patient clinical status in response to the trends of a plurality of patient parameters. | 04-19-2012 |
20120102339 | Interface Device for Communication Between a Medical Device and a Computer - The present invention relates to an interface device and a method for communication between a medical device and a computer system. In some embodiments, the interface device comprises a conversion device and/or a processor-transceiver and a memory in electrical communication with the conversion device, wherein the memory contains data to instruct the conversion device and/or the processor transceiver how to communicate with the medical device. | 04-26-2012 |
20120331132 | NETWORK MONITORING SYSTEMS FOR MEDICAL DEVICES - A ventilator monitoring system is described for monitoring a plurality of ventilators. In one embodiment, a server including a dedicated ventilator application program for each type of ventilator, monitors a plurality of heterogeneous ventilators over a wireless network. | 12-27-2012 |
20140313054 | NETWORK MONITORING SYSTEMS FOR MEDICAL DEVICES - A ventilator monitoring system is described for monitoring a plurality of ventilators. In one embodiment, a server including a dedicated ventilator application program tor each type of ventilator, monitors a plurality of heterogeneous ventilators over a wireless network. | 10-23-2014 |
20140321262 | Network Monitoring for Active Medical Device Alarms - A system and method for monitoring a patient over a network. In one embodiment, the system includes a network; a connection device configured to connect to the network, the connection device including a reporter that transmits reports to the network; a user interface device in communication with the network, the user interface device including a display and a gateway; a network management system in communication with the network, the network management system comprising an active alert system list listing each user interface device having a gateway that has registered with the network management system; a communications interface in communication with the network, the communications interface receiving reports from the reporter and transmitting reports to the network management system; wherein the network management system determines if a report received from the communications interface is to be sent to the user interface device as an alert. | 10-30-2014 |